OBJECTIVE: Obesity, which is frequently associated with diabetes, hypertension and cardiovascular diseases, is primarily the result of a net excess of caloric intake over energy expenditure. Human obesity is highly heritable, but the specific genes mediating susceptibility in non-syndromic obesity remain unclear. We tested candidate genes in pathways related to food intake and energy expenditure for association with body mass index (BMI). METHODS: We reanalyzed 355 common genetic variants of 30 candidate genes in seven molecular pathways related to obesity in 1982 unrelated European Americans from the New York Cancer Project. Data were analyzed by using a Bayesian hierarchical generalized linear model. The BMIs were log-transformed and then adjusted for covariates, including age, age 2 , gender and diabetes status. The single-nucleotide polymorphisms (SNPs) were modeled as additive effects. RESULTS: With the stipulated adjustments, nine SNPs in eight genes were significantly associated with BMI: ghrelin (GHRL; rs35683), agouti-related peptide (AGRP; rs5030980), carboxypeptidase E (CPE; rs1946816 and rs4481204), glucagon-like peptide-1 receptor (GLP1R; rs2268641), serotonin receptors (HTR2A; rs912127), neuropeptide Y receptor (NPY5R;Y5R1c52), suppressor of cytokine signaling 3 (SOCS3; rs4969170) and signal transducer and activator of transcription 3 (STAT3; rs4796793). We also found a gender-by-SNP interaction (rs1745837 in HTR2A), which indicated that variants in the gene HTR2A had a stronger association with BMI in males. In addition, NPY1R was detected as having a significant gene effect even though none of the SNPs in this gene was significant. CONCLUSION: Variations in genes AGRP, CPE, GHRL, GLP1R, HTR2A, NPY1R, NPY5R, SOCS3 and STAT3 showed modest associations with BMI in European Americans. The pathways in which these genes participate regulate energy intake, and thus these associations are mechanistically plausible in this context.
INTRODUCTION
Obesity is primarily a result of a greater intake of calories than the energy expended. Usually defined in adults as a body mass index (BMI) 430, obesity has become a leading public health concern for both genders, all ages and all ethnic groups. 1 With current trends, by 2030, some researchers project that 86.3% of American adults will be overweight (25oBMIp30) or obese (BMI430), and that overall 51.1% will be obese. 2 Furthermore, it is predicted that there will be 1.12 billion obese individuals globally. 3 Obesity is highly associated with several major comorbidities, including diabetes, hypertension, cardiovascular and kidney diseases. 4 The total health-care costs attributable to overweight and obesity are large and are projected to grow. 2 In addition to important environmental factors, evidence from animal models to human studies suggests that genetic makeup also has an important role in the pathogenesis of obesity. 5, 6 Leptin, a 16-kDa adipocyte-derived hormone, is an important factor in regulating energy intake and energy expenditure by signaling to the hypothalamic pathways that have critical roles in obesity. 7 Advances in genotyping technology have made entire genome screening possible. With genome-wide association studies, many associations between obesity and genetic variants have been identified. [8] [9] [10] [11] Genome-wide association studies are powerful in identifying the association between diseases (or traits) and genetic variants, such as single-nucleotide polymorphisms (SNPs). Because the number of SNPs is usually much larger than the number of subjects, traditional multiple regression including all measured SNPs as predictors cannot be used. In published genome-wide association studies, simple single-marker analysis of one SNP at a time is commonly used for detecting associations. Yet, the flaws of this strategy are manifold. Because most complex traits are associated with multiple genetic variants, and each variant contributes only a very small portion of risk, single-marker analysis may not have enough power to detect the weak association of each individual variant. 12 Furthermore, human genome is well known for 'genetic redundancy'-an abundance of genes having similar roles. Disruption of a single gene may often be selectively neutral. 13 Consequently, it may take the malfunction of several genes to produce a particular disorder.
14 In addition, multipletesting penalties become a critical issue when the number of SNPs is large. The many tests, of which most correspond to unassociated SNPs, will reduce the required per-test significance level to a very small value, and therefore the power to detect truly associated SNPs is greatly compromised. To address these issues, instead of using the single-marker analysis, a promising approach would be to simultaneously model multiple SNPs in a candidate gene or a pathway. 15 Various statistical methods have been developed to analyze multiple SNPs simultaneously, 16 in which penalized 17, 18 and Bayesian 19, 20 estimation procedures have been proposed and used for variable selection or shrinkage in large p small n regressions.
Chung et al. 21 previously investigated 355 common genetic variants of 30 candidate genes in seven molecular pathways related to obesity in 1982 unrelated European Americans from the New York Cancer Project, and found that two SNPs in the ghrelin gene (GHRL) (rs35682 and rs35683) were associated with BMI in this population. In that study, the 355 SNPs were tested individually by using ordinary least squares regression combined with a false discovery rate control for multiple-testing correction. 22 To test the associations of these 355 SNPs on BMI simultaneously, we reanalyze these data here by using a Bayesian hierarchical generalized linear model (BhGLM). 19 A total of 17 709 subjects with valid data were recruited. Of these, 10 260 (57.9%) were European Americans (non-Hispanic white). Individuals at the extremes of the BMI distribution are potentially the most informative in this context and were therefore selected for initial analysis. Cancer history was by self-report and was confirmed in state cancer registries when possible. All subjects with a history of cancer were eliminated from the study groups to eliminate the possible effect of cancer and its treatment on body weight. European American subjects were sorted by ascending BMI. Subjects below the 10th percentile for BMI were not included to avoid the confounding effects of medical conditions that themselves might cause weight loss. In total, 1003 gender-and age-matched pairs of European Americans with BMI between the 10th and 30th percentiles or above the 80th percentile were selected for genotyping.
MATERIALS AND METHODS
The BMI data set used in this analysis included the descriptive and genetic information of 1982 unrelated European Americans with valid genotype data from the New York Cancer Project. 21 The phenotypic characteristics of the 1982 individuals are summarized in Table 1 . A total of 355 SNPs in 30 candidate genes selected from hypothalamic-arcuate pathways were analyzed. 21 Briefly, the candidate genes were drawn from seven functional groups related to energy homeostasis: (i) the leptin pathway, which includes the hormone leptin (LEP), its receptor (LEPR), and downstream signaling molecules (JAK2, suppressor of cytokine signaling 3 (SOCS3) and signal transducer and activator of transcription 3 (STAT3)); (ii) the melanocortin pathway, which includes the agouti-related peptide (AGRP), melanocortin 4 receptor (MC4R), proopiomelanocortin (POMC) and carboxypeptidase E (CPE) that processes preprohormones; (iii) the GHRL pathway, which includes GHRL and its receptor GHSR; (iv) the glucagon-like peptide 1 pathway, which includes GCG and its receptor GLP1R; (v) the neuropeptide Y pathway, which includes the receptors NPY1R and NPY5R; (vi) the serotonin pathway, which includes the serotonin receptors HTR2A and HTR2C; (vii) the Bardet-Biedl group, which includes the genes identified for BBS1, BBS2, ARL6, BBS4, BBS5, MKKS, BBS7 and TTC8. The list of the SNPs and the selection criteria can be found in Chung et al's 21 article and supplementary materials.
Statistical analysis
We jointly estimated the effects of all the SNPs and some covariates, including age, age 2 , gender and diabetes status, and gender-SNP interactions. Because the model included a large number of effects, a classic generalized linear model approach would have unstable estimation. Therefore, we used a Bayesian hierarchical modeling approach, in which the effects are themselves modeled. The hierarchical level that models the effects themselves is referred to as prior distributions. 19 Because the priors constrain effects to lie in a reasonable range and provide additional information to estimate them, the hierarchical approach can yield stable and more precise estimates. 23, 24 The Bayesian hierarchical models described in Yi et al. 19 can simultaneously estimate the genetic effects of individual variants and the overall effects of genetic variants within a gene (referred to as gene effects). With the estimated coefficients and their s.d., the P-values can be calculated by using Wald statistics as in the classical framework to test whether an estimated coefficient is significantly different from zero. These P-values have similar interpretation to the classical P-values; however, they are calculated based on both data and priors. The prior distributions and the computational algorithm are fully described in Yi et al. 19 and were implemented in the R package BhGLM (http:// www.ssg.uab.edu/bhglm). The package BhGLM provides several prior distributions for setting up the hierarchical models and a computationally efficient algorithm for fitting the models. Because the analyses with different priors yielded similar results (data not shown), we provided the results from the analysis using the commonly used double-exponential prior distributions. For genetic association analyses, it is reasonable to assume that most of the genetic markers have no or very weak effects on the phenotype, whereas only some have noticeable effects. The doubleexponential prior with one-scale parameter has higher mass around zero (leading to stronger shrinkage toward zero for the effect estimates of markers with no or very weak effects) and thicker tails (leading to less shrinkage for estimates of markers with sizable effects), and the larger scale parameter forces more coefficients to be near zero. In the BhGLM package, the scale parameter of double-exponential prior can be considered as a random variable with a gamma distribution and estimated from the data with an EM algorithm. The estimation of the scale parameter greatly decreases the arbitrariness of the shrinkage than using fixed values for the prior.
We transformed all the input variables to a roughly common scale. The BMIs were log-transformed to normalize the residual distribution and then standardized by centering and dividing by two s.d. The covariates included age, gender and diabetes status, the same as in Chung et al.'s article. 21 Age was rescaled to have a mean of 0 and a s.d. of 0.5. There were no missing data for the covariates.
Among the 355 SNPs, 17 were not polymorphic in the sense that all study subjects were homozygous for the major allele. These SNPs were excluded from further analyses. Among the remaining 338 SNPs, 154 SNPs contained missing values and the missing rate for each SNP ranged from 0.05 to 0.75%. The SNPs were modeled with additive effects, that is, the common homozygote, the heterozygote and the rare homozygote were coded as 0, 1 and 2, respectively. The missing genotypes were replaced with an observed mean of the predictor in the whole sample.
To assess the overall effect of multiple genetic variants in a particular gene on the phenotype, the 338 SNPs were grouped into 30 genes on the basis of their chromosomal positions (the gene names, chromosomal locations and coordinates according to NCBI Human Genome Build 35, http://www.ncbi.nlm.nih.gov/mapview/stats/BuildStats.cgi?taxid= 9606&build=35&ver=1). Gender-SNP interactions were also investigated. Table 2 ). The positive estimate of the age effect (P ¼ 0.0156) and the negative estimate of the age 2 effect (P ¼ 0.0266) suggested a positive effect of age on BMI until a turning point of about 70 years old. The diabetic individuals had larger BMI values compared with the nondiabetic individuals (Po0.0001). After control for other predictors, the males had slightly but significantly larger BMI values compared with the females (P ¼ 0.0028).
Among the 338 SNPs, rs5030980 in gene AGRP, rs1946816 and rs4481204 in CPE, rs35683 in GHRL, rs912127 in HTR2A, rs2268641 in GLP1R, Y5R1c52 in NPY5R, rs4969170 in SOCS3 and rs4796793 in STAT3 were significantly associated with BMI, either positively or negatively ( Table 3) .
The associations with individual SNPs could be weak and therefore were difficult to detect when the SNPs were tested separately. The BhGLM method allowed us to investigate the association of a gene by testing the overall association of all SNPs in that gene with the phenotype and at the same time pinpointing the significant SNPs. In our analysis, four genes were significantly associated with BMI: AGRP, CPE, GHRL and NPY1R (Table 4) .
A significant interaction between SNP rs1745837 in HTR2A and gender was also detected (Table 5 ). This finding suggested that variants in HTR2A could have stronger effects on BMI in males than in females.
DISCUSSION
Obesity, an important risk factor for diabetes, hypertension, cardiovascular and kidney diseases, has become a global public health concern. Genetic association studies may provide insight into the pathogenesis and prevention of obesity. Chung et al. 21 performed a genetic study on BMI in European Americans and tested the effects of 355 selected SNPs individually, with target genes in target pathways. They found that two SNPs in GHRL (rs35682 and rs35683) were associated with BMI in the sample of New York European Americans. Using the same data, we tested the effects of the SNPs simultaneously with a new Bayesian hierarchical model, and found more statistically significant genetic associations. In addition to the SNP in GHRL (rs35683), we found that SNPs in AGRP (rs5030980), CPE (rs1946816 and rs4481204), GLP1R (rs2268641), HTR2A (rs912127), NPY5R (Y5R1c52), SOCS3 (rs4969170) and STAT3 (rs4796793) were significantly associated with BMI in the same sample of New York European Americans. Gene effects on BMI were also detected in AGRP, CPE, GHRL and NPY1R. Our results further suggested a gender-by-SNP interaction for rs1745837 in HTR2A, which implied that variants in HTR2A might have stronger effects on BMI in men than in women. However, only 3% of the variance in BMI could be explained by the variants of these genes on the basis of our models (each SNP contributed only 0.2-0.3% of the variance on average), which suggests that more genes, their interactions and their interactions with enviromental factors could be involved in the pathogenesis of obesity.
GHRL is an endogenous peptide that stimulates growth hormone secretion and enhances appetite. Polymorphisms in GHRL have previously been reported to be associated with obesity in different populations. 21, [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] In Chung et al., 21 both rs35682 and rs35683 were found to be significantly associated with BMI on the basis of the individual SNP tests. Because these two SNPs are closely located (within 600 base pairs) in intron 2 and intron 3, they are highly correlated (r 2 ¼ 0.96, Po0.0001, a high level of linkage disequilibrium). Either one can be considered to be the surrogate variable of the other in a multiple regression. Therefore, Genetic association of obesity P Li et al when the effects of rs35682 and rs35683 were simultaneously modeled with the BhGLM method, only one (rs35683) stood out. AGRP is an endogenous antagonist of melanocortin signaling and therefore stimulates appetite. The SNP rs5030980, causing the Thr67Ala mutant, was shown to have a significant association with BMI in our study. A causal effect is plausible because this is a nonsynonymous mutant. However, the effects of the Thr67Ala mutation are not consistent in the literature. [35] [36] [37] [38] The Thr67Ala AGRP polymorphism was reported to be associated with lower body weight in Quebec families 37 and in a West African population, 35 whereas no association was found between rs5030980 and BMI in Dutch adults 38 or in a Latvian population. 36 These inconsistent conclusions could be because of the different statistical models used for the analyses, different sample sizes or different effects in different populations.
The GLP1R is a key physiological regulator of insulin secretion and is a major therapeutic target for treatment of type 2 diabetes. Variation in GLP1R has been reported to alter insulin secretion in response to exogenous GLP-1 in humans 39 and to influence food intake in mice. 40 Treatment with GLP1R agonists also leads to weight loss in overweight or obese patients with or without type 2 diabetes mellitus. 41 Our results further suggest that genetic variation in GLP1R is associated with obesity in European Americans.
Leptin and its downstream signaling molecules JAK2, SOCS3 and STAT3 have an important role in regulating energy intake and energy expenditure. 7, 42 Polymorphisms near SOCS3 were reported to be associated with obesity and glucose homeostasis traits in Hispanic Americans, 43 and STAT3 polymorphisms were reported to be associated with abdominal obesity in French adults. 44 Our findings further suggest the association of polymorphisms in SOCS3 and STAT3 with BMI in European Americans living in the New York area.
Serotonin (5-hydroxytryptamine) is a neurotransmitter regulating many physiological processes, such as sleep, appetite and hormone secretion. Serotonin receptor 2A (HTR2A) and 5-hydroxytryptamine are involved in regulating cortisol secretion, 45 which may have a pathogenetic role in abdominal obesity. 46 Polymorphisms in HTR2A have been found to be associated with abdominal obesity and BMI in Swedish adults, 47, 48 and with increased energy and fat intake in French children. 49 We found a novel interaction of an SNP in this gene with gender, which indicated that variants in this gene might have different effects on BMI in men and women.
Neuropeptide Y and neuropeptide Y receptor (NPY1R and NPY5R) have a key role in the physiological control of energy homeostasis. 50 It has been reported that polymorphisms in NPY5R are associated with obesity in Pima Indians. 51 Our models established an association between BMI and polymorphisms in NPY5R in a European American population. The effects of individual variants in NPY1R might be weak; however, a significant gene effect was detected.
CPE is an enzyme that functions in the production and activation of many neuropeptides and peptide hormones. 52 Two SNPs (rs1946816 and rs4481204) were found to be associated with BMI in the European American population by the BhGLM method. Interestingly and consistently, these two SNPs were located in a haplotype block that was associated with BMI by use of a haplotype similarity-based multimarker association test. 53 The BhGLM method also identified a signficant gene effect for CPE. In fact, some previous studies have shown that a single-point mutation in the CPE gene is sufficient to cause multiple disorders in animals, including obesity. 54, 55 In addition, other studies have reported an association of the CPE gene with human obesity and diabetes. 56, 57 Because no genetic associations with obesity for GLP1R and NPY1R have been reported in humans so far, confirmation in independent study populations is needed, although our results are biologically plausible. Note that most of the SNPs we found to be significantly associated with BMI are located in introns or nontranscribed regions (Table 3) ; these SNPs may cause changes in splicing or expression. The association of these SNPs may also derive from the effects of causal variants that are in linkage disequilibrium with them. Because our cross-sectional data came from a prospective cohort, when new data become available, a further prospective analysis will be conducted to reinforce the strength of our findings.
The most commonly used approach in genetic association studies is to consider one or a few genetic variants at a time. Despite the ease of implementation, this approach can produce misleading results. In the present study, we used the BhGLM method to simultaneously test the associations of multiple variants. This method put prior information on the parameters to control the compexity of the model and handle high-dimensional and correlated variables. The method has been implemented in the freely available R package BhGLM. 19 This method can be powerful for detecting weak associations of individual SNPs with joint consideration of multiple SNPs. BhGLM provides flexibility by including most versions of the penalized regression procedures with different prior specification or further modeling on the hyperparameters. 19, 20, [58] [59] [60] Another advantage of BhGLM is that the parameters and the hyperparameters can be estimated from the data by the use of an EM algorithm rather than by giving fixed values, which greatly eliminates the arbitrariness of the shrinkage. Some genetic effects may be too weak to be detected individually, and therefore the overall (gene or group) effects will be preferred. This is testified too in our study by the detection of a gene effect of NPY1R but no individual SNP effect.
In summary, we used a BhGLM method to test the genetic association of BMI in European Americans living in New York and found that genetic variants in or close to the genes AGRP, CPE, GHRL, GLP1R, HTR2A, NPY1R, NPY5R, SOCS3 and STAT3 were significantly associated with BMI. The underlying mechanism of this association, however, requires further investigation.
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